04 – COVID 19, Crisis and Supply Chain Management
04 – COVID 19, Crisis and Supply Chain Management
€0,00
This is the last edition in our series of special COVID-19 newsletters on what companies could consider now and over the next few months to stabilize the company and to build for future success. In previous editions, we have been looking at immediate actions concerning financial management, which was then followed by two editions around strategic review and implementation to support future growth.
Description
TRANSFORMING IN TIMES OF CRISIS
This is the last edition in our series of special COVID-19 newsletters on what companies could consider now and over the next few months to stabilize the company and to build for future success. In previous editions, we have been looking at immediate actions concerning financial management, which was then followed by two editions around strategic review and implementation to support future growth. This edition now focuses on another important area for life science companies, the overall supply chain. After the recent disruptions and occasional breakdowns in global supply chains, will there be a quick recovery soon, and can the supply chain’s resilience be strengthened in case a new wave of disruption would occur?…
Related products
-
02 – COVID 19, Crisis and Strategy
€0,00 Add to cart
02 - COVID 19, Crisis and Strategy
€0,00In the past few weeks, we have overheard many people discussing how they have experienced an excellent performance in March ...- Categories: COVID-19 crisis.
- Tags: company strategy, external environment, PESTLE analysis, strategy, Strategy review.
-
01 – COVID 19, Crisis and Financial Management
€0,00 Add to cart
01 - COVID 19, Crisis and Financial Management
€0,00When preparing for crises, it is critical to fix the roof before it starts raining. Many of us have been ...- Categories: COVID-19 crisis.
- Tags: cash, cash flow projection, Financial Management, liquidity, working capital, working capital forecast.
-
03 – COVID 19, Crisis and Strategy Implementation
€0,00 Add to cart
03 - COVID 19, Crisis and Strategy Implementation
€0,00While writing this plan, we have been intentional in considering the change management aspect. We believe that what most of ...
Die in Starnberg ansässige M&A Beratung für die pharmazeutische Industrie, MANLIK PHARMA CONSULTANTS GMBH, begleitete das Familienunternehmen Dr. Willmar Schwabe GmbH & Co. KG im Verkaufsprozess des Unternehmens Spitzner in Kombination mit dem Carve-Out des Produktionsstandortes Ettlingen an die neu gegründete W. Spitzner Arzneimittelfabrik GmbH.